Pharma deals on the up

Deal volume was up 20% in the pharmaceutical and life sciences sector in the last 12 months as dealmakers grew more comfortable with uncertainty, according to a report from PwC.

This report is entitled Pharmaceutical and life sciences: US Deals 2024 midyear outlook. It finds that, with pharma and life sciences deal volume growing to $209 billion over the past year, the industry is learning to adapt to challenges such as US Federal Trade Commission regulations and the evolving healthcare marketplace.

The growth can also be attributed to an increase in new therapeutic approvals, namely GLP-1s in the obesity and diabetedys space, which have had a big impact on the market. Industry players have pivoted further and faster toward high-innovation areas with the potential to fill looming loss-of-exclusivity gaps in the latter half of the decade, the report found.